Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

According to the authors, the research opens up new possibilities for developing the next generation of ChE inhibitors that ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...

Certain neurodegenerative disorders are characterized by the progressive accumulation of insoluble deposits of distinct misfolded proteins. In general, mutations causing inherited forms of the ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by the buildup of amyloid-beta plaques and tau protein tangles in the ...

Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults. AD begins ...